IL150566A0 - Nucleic acids and polypeptides and nogo-receptor proteins - Google Patents

Nucleic acids and polypeptides and nogo-receptor proteins

Info

Publication number
IL150566A0
IL150566A0 IL15056601A IL15056601A IL150566A0 IL 150566 A0 IL150566 A0 IL 150566A0 IL 15056601 A IL15056601 A IL 15056601A IL 15056601 A IL15056601 A IL 15056601A IL 150566 A0 IL150566 A0 IL 150566A0
Authority
IL
Israel
Prior art keywords
nogo
receptor proteins
disclosed
polypeptides
nucleic acids
Prior art date
Application number
IL15056601A
Other languages
English (en)
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Publication of IL150566A0 publication Critical patent/IL150566A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
IL15056601A 2000-01-12 2001-01-12 Nucleic acids and polypeptides and nogo-receptor proteins IL150566A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17570700P 2000-01-12 2000-01-12
US20736600P 2000-05-26 2000-05-26
US23637800P 2000-09-29 2000-09-29
PCT/US2001/001041 WO2001051520A2 (en) 2000-01-12 2001-01-12 Nogo receptor-mediated blockade of axonal growth

Publications (1)

Publication Number Publication Date
IL150566A0 true IL150566A0 (en) 2003-02-12

Family

ID=27390581

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15056601A IL150566A0 (en) 2000-01-12 2001-01-12 Nucleic acids and polypeptides and nogo-receptor proteins
IL150566A IL150566A (en) 2000-01-12 2002-07-03 Nucleic acids and polypeptides and nogo receptor proteins

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL150566A IL150566A (en) 2000-01-12 2002-07-03 Nucleic acids and polypeptides and nogo receptor proteins

Country Status (27)

Country Link
US (1) US20020012965A1 (OSRAM)
EP (2) EP1248803B1 (OSRAM)
JP (1) JP4763207B2 (OSRAM)
KR (1) KR100828058B1 (OSRAM)
CN (1) CN100354307C (OSRAM)
AT (1) ATE466882T1 (OSRAM)
AU (1) AU784349C (OSRAM)
BG (1) BG106907A (OSRAM)
BR (1) BR0107613A (OSRAM)
CA (1) CA2397199C (OSRAM)
CZ (1) CZ20022438A3 (OSRAM)
DE (1) DE60142023D1 (OSRAM)
EA (1) EA008480B1 (OSRAM)
EE (1) EE200200386A (OSRAM)
ES (1) ES2341842T3 (OSRAM)
GE (1) GEP20063830B (OSRAM)
HK (1) HK1051543A1 (OSRAM)
HU (1) HUP0203863A3 (OSRAM)
IL (2) IL150566A0 (OSRAM)
IS (1) IS6455A (OSRAM)
MX (1) MXPA02006885A (OSRAM)
NO (1) NO20023387L (OSRAM)
NZ (2) NZ520065A (OSRAM)
PL (1) PL356887A1 (OSRAM)
SK (1) SK9992002A3 (OSRAM)
WO (1) WO2001051520A2 (OSRAM)
YU (1) YU53502A (OSRAM)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999066041A1 (en) 1998-06-16 1999-12-23 Human Genome Sciences, Inc. 94 human secreted proteins
US7723488B2 (en) 1998-03-27 2010-05-25 Genentech, Inc. Monoclonal antibodies to secreted and transmembrane polypeptides
US7371836B2 (en) 1998-03-27 2008-05-13 Genentech, Inc. PRO526 nucleic acids
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
DE60142023D1 (de) * 2000-01-12 2010-06-17 Univ Yale Nogo rezeptor-vermittelte blockade des axonalen wachstums
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
WO2002081628A2 (en) * 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
NZ525422A (en) 2000-10-06 2006-09-29 Biogen Idec Inc Isolated polynucleotides comprising a nucleic acid which encodes a polypeptide which modulates axonal growth in CNS neurons
GB0101312D0 (en) 2001-01-18 2001-02-28 Glaxo Group Ltd Assay
GB0101313D0 (en) * 2001-01-18 2001-02-28 Glaxo Group Ltd Assay
JP2005507246A (ja) * 2001-08-27 2005-03-17 ノバルティス アクチエンゲゼルシャフト Ｎｏｇｏレセプターホモログおよびそれらの使用
US7309485B2 (en) * 2001-12-03 2007-12-18 Children's Medical Center Corporation Reducing myelin-mediated inhibition of axon regeneration
FR2841261B1 (fr) * 2002-06-25 2004-08-27 Univ Pasteur Compositions et methodes pour detecter les pathologies affectant la transmission neuromusculaire
PT1534736E (pt) * 2002-08-10 2010-09-07 Univ Yale Antagonistas do receptor nogo
EP1534736B1 (en) * 2002-08-10 2010-06-02 Yale University Nogo receptor antagonists
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
ATE466870T1 (de) * 2002-12-06 2010-05-15 Zhi Cheng Xiao Peptide und deren verwendung in der behandlung von krankheiten des zentralen nervensystems
US7842666B2 (en) * 2002-12-20 2010-11-30 Research Foundation Of City University Of New York Inhibitors of myelin-associated glycoprotein (MAG) activity for regulating neural growth and regeneration
ES2537015T3 (es) 2003-03-19 2015-06-01 Biogen Ma Inc. Proteína de unión del receptor de NOGO
US7541335B2 (en) * 2003-04-04 2009-06-02 University Of Rochester Nogo-receptors and methods of use
RS20050774A (sr) * 2003-04-16 2007-12-31 Biogen Idec Ma Inc., Antagonisti nogo receptora za tretman stanja sa amiloidnim plakovima
CA2525966A1 (en) * 2003-05-15 2004-12-23 The Board Of Trustees Of The Leland Stanford Junior University Novel immunomodulating peptide
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
MX348062B (es) * 2003-05-16 2017-05-26 Acorda Therapeutics Inc Mutantes que degradan proteoglicanos para tratamiento del snc.
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
US8912144B2 (en) * 2003-12-16 2014-12-16 Children's Medical Center Corporation Method for treating stroke via administration of NEP1-40 and inosine
WO2005059515A2 (en) * 2003-12-16 2005-06-30 Children's Medical Center Corporation Method for treating neurological disorders
EP1776136B1 (en) 2004-06-24 2012-10-03 Biogen Idec MA Inc. Treatment of conditions involving demyelination
CA2576193A1 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
AU2005299974A1 (en) * 2004-10-01 2006-05-04 Yale University Nogo-A polypeptide fragments, variant Nogo receptor-1 polypeptides, and uses thereof
WO2006059959A1 (en) * 2004-12-01 2006-06-08 National University Of Singapore Nogo a protein fragments as neuronal network-interacting peptides
WO2007008732A2 (en) * 2005-07-07 2007-01-18 Yale University Compositions and methods for suppressing axonal growth inhibition
DK1904104T3 (da) 2005-07-08 2013-11-11 Biogen Idec Inc SP35-antistoffer og anvendelser heraf
AU2006294755B2 (en) 2005-09-26 2012-04-19 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
EP2526968A3 (en) 2006-01-27 2013-05-22 Biogen Idec MA Inc. Nogo receptor antagonists
EP2023735A4 (en) * 2006-05-15 2011-05-25 Biogen Idec Inc USE OF ANTAGONISTS OF THE NOGO RECEPTOR 1 (NGR1) TO PROMOTE THE SURVIVAL OF OLIGODENDROCYTES
WO2008013782A2 (en) 2006-07-24 2008-01-31 Biogen Idec Ma Inc. Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of sp35 or trka antagonists
CA2987970A1 (en) 2006-11-21 2008-05-29 Abbvie Inc. Neutralizing monoclonal antibodies against the nogo-66 receptor (ngr) and uses thereof
EP2276500A4 (en) 2008-03-13 2015-03-04 Univ Yale REACTIVATION OF AXON GROWTH AND AXON RECOVERY IN CHRONIC REVERSE MARKET INJURIES
US20090285803A1 (en) * 2008-05-13 2009-11-19 Jasvinder Atwal ANTI-PirB ANTIBODIES
AU2009269099B2 (en) 2008-07-09 2016-03-10 Biogen Ma Inc. Compositions comprising antibodies to LINGO or fragments thereof
CA2873623C (en) 2012-05-14 2021-11-09 Biogen Idec Ma Inc. Lingo-2 antagonists for treatment of conditions involving motor neurons
CN104935294B (zh) * 2014-03-20 2018-07-20 晶宏半导体股份有限公司 振荡器
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
CN105061560B (zh) * 2015-07-17 2018-10-09 暨南大学 一种Nogo-A受体结合肽及其衍生物与应用
CN113527462B (zh) * 2020-04-22 2023-05-23 北京大学 一种具有镇痛作用的小分子肽及其特异性抗体

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4839288A (en) 1986-01-22 1989-06-13 Institut Pasteur Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes
US5466585A (en) 1986-04-15 1995-11-14 Ciba-Geigy Corporation Interferon-induced human protein in pure form, monoclonal antibodies thereto, and test kits containing these antibodies
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
WO1989007150A1 (en) 1988-02-05 1989-08-10 The Trustees Of Columbia University In The City Of Retroviral packaging cell lines and processes of using same
WO1990002806A1 (en) 1988-09-01 1990-03-22 Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
CA1341050C (en) 1988-11-04 2000-07-11 Martin E. Schwab Neurite growth regulatory factors
DE68923362T2 (de) 1988-11-04 1996-03-28 Zuerich Erziehungsdirektion Wachstumsregelfaktoren für neuriten.
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5723719A (en) 1991-08-08 1998-03-03 Health Research Inc. Transgenic mouse as model for diseases involving dopaminergic dysfunction
DE4126968A1 (de) 1991-08-14 1993-02-18 Detlev Prof Dr Med Ganten Transgene ratten, die in ihrem genom mindestens ein menschliches gen enthalten, das an der blutdruckregulation beteiligt ist
JPH07502164A (ja) 1991-09-20 1995-03-09 フレッド ハッチンソン キャンサー リサーチ センター ヒトサイクリンｅ
ATE243746T1 (de) 1992-01-07 2003-07-15 Elan Pharm Inc Transgene tiermodelle fur alzheimer-krankheit
US5733720A (en) 1992-06-18 1998-03-31 Washington University Genetically engineered cell lines for detecting infectious herpesvirus and methods therefor
US5602307A (en) 1992-08-12 1997-02-11 Baylor College Of Medicine Non-human animal having predefined allele of a cellular adhesion gene
US5731490A (en) 1992-09-29 1998-03-24 The Ontario Cancer Institute Mutant mouse lacking the expression of interferon regulatory factor 1 (IRF-1)
EP0634939A1 (en) 1993-02-11 1995-01-25 Erziehungsdirektion Of The Canton Zurich A combination of neurotrophin and antibody directed toward myelin-associated neurite growth inhibitory protein promotes central nervous system regeneration
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
DK75393D0 (da) 1993-06-24 1993-06-24 Symbicom Ab Production of protein
PT725682E (pt) 1993-10-28 2002-09-30 Houston Advanced Res Ct Dispositivo poroso microfabricado de escoamento
NZ281041A (en) 1994-03-09 1998-04-27 Abbott Lab Non-human mammals transformed with a catalytic entity of enzymes or antibodies to produce a heterologous product in the animals milk
FR2718329B1 (fr) 1994-03-21 2002-09-20 Rhone Poulenc Rorer Sa Lapin transgénique sensibilisé aux dyslipoprotéinémies.
US5908969A (en) 1994-05-13 1999-06-01 The Regents Of The University Of California Method of detecting prions in a sample and transgenic animal used for same
WO2000037638A2 (en) * 1998-12-22 2000-06-29 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
WO2000073452A2 (en) * 1999-06-02 2000-12-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US5728915A (en) 1995-05-08 1998-03-17 Children's Hospital, Inc. Transgenic mice which express simian SV 40 T-antigen under control of the retinoblastoma gene promoter
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US5961976A (en) 1996-06-03 1999-10-05 United Biomedical, Inc. Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV
US5858708A (en) 1996-08-12 1999-01-12 Bandman; Olga Polynucleotides encoding two novel human neuroendocrine-specific proteins
WO1999066041A1 (en) * 1998-06-16 1999-12-23 Human Genome Sciences, Inc. 94 human secreted proteins
WO2000070050A1 (en) * 1999-05-14 2000-11-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
AU736506B2 (en) * 1997-12-03 2001-07-26 Genentech Inc. Polypeptides and nucleic acids encoding the same
PT1490386E (pt) * 1998-03-10 2008-11-24 Genentech Inc Novos polipéptidos e ácidos nucleicos que os codificam
AU762055B2 (en) * 1998-03-10 2003-06-19 Genentech Inc. Novel polypeptides and nucleic acids encoding the same
WO1999053945A1 (en) 1998-04-16 1999-10-28 Samuel David Neuron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration
CA2324297A1 (en) * 1998-04-23 1999-10-28 Genentech, Inc. Sh2 domain-containing peptides
AU769166B2 (en) * 1998-04-24 2004-01-15 Genentech Inc. Fizz proteins
AU761340B2 (en) * 1998-06-02 2003-06-05 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
ES2529196T3 (es) * 1998-11-06 2015-02-17 University Of Zurich Secuencias de nucleótidos y proteínas de genes Nogo y métodos basados en estas
CA2347835A1 (en) * 1998-12-01 2000-06-08 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
CA2361840A1 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2362427A1 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2383592A1 (en) * 1999-03-31 2000-10-05 Curagen Corporation 2384891 acids including open reading frames encoding polypeptides; orfx
AU6394400A (en) * 1999-07-30 2001-02-19 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
DE60142023D1 (de) * 2000-01-12 2010-06-17 Univ Yale Nogo rezeptor-vermittelte blockade des axonalen wachstums

Also Published As

Publication number Publication date
CZ20022438A3 (cs) 2002-10-16
YU53502A (sh) 2005-11-28
CA2397199A1 (en) 2001-07-19
HUP0203863A2 (hu) 2003-03-28
NO20023387D0 (no) 2002-07-12
DE60142023D1 (de) 2010-06-17
CN100354307C (zh) 2007-12-12
GEP20063830B (en) 2006-05-25
BR0107613A (pt) 2002-11-19
CN1404488A (zh) 2003-03-19
WO2001051520A9 (en) 2002-07-18
KR20020097157A (ko) 2002-12-31
WO2001051520A2 (en) 2001-07-19
CA2397199C (en) 2013-12-24
NZ541694A (en) 2006-08-31
NZ520065A (en) 2006-02-24
IL150566A (en) 2008-03-20
JP2003519481A (ja) 2003-06-24
ATE466882T1 (de) 2010-05-15
EP1248803B1 (en) 2010-05-05
MXPA02006885A (es) 2004-04-05
EA008480B1 (ru) 2007-06-29
EA200200755A1 (ru) 2002-12-26
HK1051543A1 (zh) 2003-08-08
EP1248803A2 (en) 2002-10-16
AU784349C (en) 2006-09-28
NO20023387L (no) 2002-09-11
IS6455A (is) 2002-07-03
WO2001051520A3 (en) 2002-04-18
JP4763207B2 (ja) 2011-08-31
SK9992002A3 (en) 2003-05-02
AU784349B2 (en) 2006-03-16
BG106907A (bg) 2003-05-30
PL356887A1 (en) 2004-07-12
EE200200386A (et) 2003-12-15
ES2341842T3 (es) 2010-06-29
KR100828058B1 (ko) 2008-05-09
HUP0203863A3 (en) 2008-03-28
EP2163561A1 (en) 2010-03-17
AU2940101A (en) 2001-07-24
US20020012965A1 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
IL150566A0 (en) Nucleic acids and polypeptides and nogo-receptor proteins
WO2003031462A3 (en) Nogo receptor-mediated blockade of axonal growth
AU1153902A (en) Nogo receptor homologs
WO2000040614A3 (en) Characterization of the soc/crac calcium channel protein family
NZ270659A (en) Mammalian protein which binds to a gst-fkbp-rapamycin complex, dna therefor and diagnostic compositions
MX344216B (es) Productos geneticos expresados de forma diferencial en tumores y su uso.
AU1922101A (en) Human fgf-21 gene and gene expression products
WO1998049300A3 (en) Truncated vegf-related proteins
WO2002044320A3 (en) Human elongase genes and uses thereof
WO1998021972A3 (de) Verbindungen mit verbesserter knorpel- und/oder knocheninduzierender aktivität
DE69835680D1 (de) Therapeutische verwendung von smr1 protein und seinen aktiven derivaten
ATE300619T1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
WO2000077239A3 (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
WO2001008635A3 (en) Calcium channel transport polynucleotides, polypeptides, and antibodies
WO2000061774A3 (en) Bone morphogenic proteins
WO2000065028A3 (en) TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR
UA72875C2 (uk) БІЛКИ, ЯКІ ЗВ'ЯЗУЮТЬСЯ З <font face="Symbol">b</font>-АМІЛОЇДНИМ ПЕПТИДОМ ТА ПОЛІНУКЛЕОТИДИ, ЩО ЇХ КОДУЮТЬ
DE69328060D1 (de) Angiotensin-II Typ-1 Rezeptor und dessen Herstellung
WO2001000638A3 (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
WO2002061086A3 (en) Human leucine-rich repeat containing protein expressed predominately in small intestine, hlrrsi1
WO2000042165A3 (en) Bone marrow-specific protein
WO1999046381A3 (en) Human fgf gene and gene expression products
WO2002052011A3 (en) A novel human leucine-rich repeat containing protein expressed predominately in bone marrow, hlrrbm1
WO2002000834A3 (fr) Nouveau polypeptide, proteine phosphatase humaine 9.68, et polynucleotide codant ce polypeptide
WO2003044160A3 (en) Novel molecules of the card related protein family and uses thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed